Richard C. Malabre

CIK: 0002007730

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (62.5%)

Position reduction

Option Exercises (M)1 (12.5%)

Derivative conversions

Awards (A)2 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AKBA

Akebia Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

AKBA
Akebia Therapeutics, Inc.
Feb 2, 2026
Sale(S)
Direct
36.1K shares at avg. $1.39$50K
AKBA
Akebia Therapeutics, Inc.
Feb 2, 2026
Sale(S)
Direct
13.4K shares at avg. $1.39$19K
AKBA
Akebia Therapeutics, Inc.
Jan 30, 2026
Award(A)
Direct
79K shares-
AKBA
Akebia Therapeutics, Inc.
Jun 9, 2025
Sale(S)
Direct
15K shares at avg. $4.01$60K
AKBA
Akebia Therapeutics, Inc.
Jun 9, 2025
Exercise(M)
Direct
15K shares at avg. $1.68$25K
AKBA
Akebia Therapeutics, Inc.
Jun 4, 2025
Sale(S)
Direct
13.3K shares at avg. $3.53$47K
AKBA
Akebia Therapeutics, Inc.
Feb 3, 2025
Sale(S)
Direct
30.2K shares at avg. $2.10$63K
AKBA
Akebia Therapeutics, Inc.
Jan 31, 2025
Award(A)
Direct
85K shares-

		Type	Shares	Price		Ownership
Feb 2, 2026	AKBA Akebia Therapeutics, Inc.	Sale(S)	36,142	$1.39	$50,237	Direct
Feb 2, 2026	AKBA Akebia Therapeutics, Inc.	Sale(S)	13,382	$1.39	$18,601	Direct
Jan 30, 2026	AKBA Akebia Therapeutics, Inc.	Award(A)	79,000	-	$0	Direct
Jun 9, 2025	AKBA Akebia Therapeutics, Inc.	Sale(S)	15,000	$4.01	$60,150	Direct
Jun 9, 2025	AKBA Akebia Therapeutics, Inc.	Exercise(M)	15,000	$1.68	$25,200	Direct
Jun 4, 2025	AKBA Akebia Therapeutics, Inc.	Sale(S)	13,334	$3.53	$47,069	Direct
Feb 3, 2025	AKBA Akebia Therapeutics, Inc.	Sale(S)	30,202	$2.10	$63,424	Direct
Jan 31, 2025	AKBA Akebia Therapeutics, Inc.	Award(A)	85,000	-	-	Direct

1-8 of 8 transactions

About Malabre Richard C

Malabre Richard C (SEC CIK 0002007730) files insider reports with the SEC as SVP, Chief Accounting Officer of Akebia Therapeutics, Inc. (AKBA).

Signal8 holds 5 ownership filings by Malabre Richard C, all Form 4s, filed between Feb 4, 2025 and Feb 4, 2026. Those filings report 8 transactions, from Jan 31, 2025 to Feb 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Malabre Richard C's filings is in CAMBRIDGE, MA.

Recent filings by Malabre Richard C

Feb 2, 2026: Open-market sales of AKBA shares (2 lines, Form 4, code S).
Jan 30, 2026: Grant or award of AKBA shares (Form 4, code A).
Jun 9, 2025: Open-market sale of AKBA shares (Form 4, code S).
Jun 9, 2025: Option exercise of AKBA shares (Form 4, code M).
Jun 4, 2025: Open-market sale of AKBA shares (Form 4, code S).

Other insiders filing for Akebia Therapeutics, Inc. (AKBA)

Butler John P., CEO and President
Ostrowski Erik, SVP, CFO, CBO & Treasurer
Wolf Myles, Director
Smith Cynthia, Director
ROGERS MICHAEL W, Director
FRIESON RON, Director

How to read Form 4 transaction codes